BIG Impact invests in autoimmune diagnostics and drug discovery startup AOI Biosciences
Reuters2026/09/15 00:19- BIG Impact Inc completed an investment in AOI Biosciences, a Japan-based diagnostics and drug-discovery company focused on autoimmune diseases.
- AOI Biosciences commercializes proprietary antibody testing with domestic and overseas medical institutions.
- The company is building a drug-discovery platform using quantum-related technology, targeting autoimmune disease and infectious disease programs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Delta Thailand returns to FTSE4Good ESG index for eighth time
Impact Biomedical to execute 1-for-12.62 reverse stock split Sept. 23
Titomic wins US$5 million U.S. Air Force contract for cold spray system at Tinker AFB
European streaming competition intensifies as Comcast and Paramount consider shutting down their joint platform SkyShowtime
NBCUniversal, a subsidiary of Comcast, and Paramount are considering gradually shutting down their joint streaming platform SkyShowtime, which offers series and movie streaming services in the European market.
Crypto prices
More
